Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Non-Current Liabilities (2016 - 2021)

OptimizeRx's Total Non-Current Liabilities history spans 12 years, with the latest figure at $260614.0 for Q3 2021.

  • On a quarterly basis, Total Non-Current Liabilities fell 26.92% to $260614.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $260614.0, a 26.92% decrease, with the full-year FY2020 number at $325533.0, down 94.26% from a year prior.
  • Total Non-Current Liabilities hit $260614.0 in Q3 2021 for OptimizeRx, down from $282934.0 in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for OPRX hit a ceiling of $5.7 million in Q4 2019 and a floor of $260614.0 in Q3 2021.
  • Historically, Total Non-Current Liabilities has averaged $1.6 million across 5 years, with a median of $1.6 million in 2017.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 512.12% in 2017 and later plummeted 94.26% in 2020.
  • Tracing OPRX's Total Non-Current Liabilities over 5 years: stood at $2.3 million in 2017, then rose by 4.8% to $2.4 million in 2018, then surged by 139.69% to $5.7 million in 2019, then plummeted by 94.26% to $325533.0 in 2020, then dropped by 19.94% to $260614.0 in 2021.
  • Business Quant data shows Total Non-Current Liabilities for OPRX at $260614.0 in Q3 2021, $282934.0 in Q2 2021, and $305039.0 in Q1 2021.